Answers are grounded in this paper and cite their sources.
Animal study reveals carfilzomib induces cardiotoxicity via autophagy and PP2A signaling rather than proteasome inhibition, highlighting alternative therapeutic targets.
In this issue of Blood, Efentakis et al report using an animal model to study carfilzomib (Cfz)–induced cardiotoxicity and to demonstrate that the molecular mechanism is not related to the inhibition of the proteasome function but instead has an influence on modulation of the autophagy pathway, inactivation of AMPKα, and upregulation of PP2A phosphatase activity.1
No takes yet. Share an insight, caveat, or question.
Jan S. Moreb (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: